Package Leaflet: Information for the Patient
Memantina TecniGen 20 mg Film-Coated Tablets EFG
Memantine Hydrochloride
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet:
5 Conservation of Memantina TecniGen
How Memantina TecniGen Works
Memantina TecniGen belongs to a group of medications called anti-dementia medications.
Memory loss in Alzheimer's disease is due to an alteration in brain signals. The brain contains so-called N-methyl-D-aspartate (NMDA) receptors that participate in the transmission of important nerve signals in learning and memory. Memantina TecniGen belongs to the group of medications called NMDA receptor antagonists. Memantina TecniGen acts on these receptors, improving the transmission of nerve signals and memory.
What Memantina TecniGen is Used For
Memantina TecniGen is used in the treatment of patients with moderate to severe Alzheimer's disease.
Do Not Take Memantina TecniGen
If you are allergic to memantine hydrochloride or any of the other components of this medication (listed in section 6).
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Memantina TecniGen:
In these situations, treatment should be carefully supervised, and your doctor should regularly reassess the clinical benefit of memantine.
If you have kidney problems, your doctor should closely monitor your kidney function and, if necessary, adjust the dose of memantine.
The use of memantine with other medications such as amantadine (for the treatment of Parkinson's disease), ketamine (a medication generally used as an anesthetic), dextromethorphan (a medication for the treatment of cough), and other NMDA antagonists should be avoided.
The use of memantine is not recommended in children and adolescents under 18 years of age.
Taking Memantina TecniGen with Other Medications
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those purchased without a prescription.
In particular, the administration of memantine may produce changes in the effects of the following medications, so your doctor may need to adjust the dose:
amantadine, ketamine, dextromethorphan,
dantrolene, baclofen,
cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine,
hydrochlorothiazide (or any combination with hydrochlorothiazide),
anticholinergics (substances generally used to treat movement disorders or intestinal spasms),
anticonvulsants (substances used to prevent and eliminate seizures),
barbiturates (substances generally used to induce sleep),
dopaminergic agonists (substances such as L-dopa, bromocriptine),
neuroleptics (substances used in the treatment of mental illnesses),
oral anticoagulants.
If you are hospitalized, inform your doctor that you are taking Memantina TecniGen.
Taking Memantina TecniGen with Food, Drinks, and Alcohol
You should inform your doctor if you have recently changed or plan to change your diet substantially (e.g., from a normal diet to a strict vegetarian diet) or if you have renal tubular acidosis (RTA, excess of acid-producing substances in the blood due to kidney dysfunction) or severe urinary tract infections (urinary tract), as your doctor may need to adjust the dose of the medication.
Pregnancy, Breastfeeding, and Fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medication.
The use of memantine is not recommended in pregnant women.
Women taking Memantina TecniGen should discontinue breastfeeding.
Driving and Using Machines
Your doctor will inform you if your illness allows you to drive and use machines safely.
Additionally, Memantina TecniGen may alter your reaction ability, so driving or operating machines may be inappropriate.
Memantina TecniGen Contains Orange Yellow S (E110)
This medication may cause allergic reactions because it contains Orange Yellow S (E110). It can cause asthma, especially in patients allergic to acetylsalicylic acid.
Memantina TecniGen Contains Sodium
This medication contains less than 23 mg of sodium (1 mmol) per film-coated tablet; that is, it is essentially "sodium-free".
Follow the administration instructions of this medication exactly as indicated by your doctor. Consult your doctor or pharmacist if you have any doubts.
Posology
The recommended dose for adults and elderly patients is 20 mg administered once a day.
To reduce the risk of side effects, this dose should be achieved gradually following a daily treatment schedule. To adjust the dose, there are tablets with different doses.
At the start of treatment, you will begin taking Memantina TecniGen 5 mg film-coated tablets once a day. This dose will be increased weekly by 5 mg until the recommended maintenance dose is reached (20 mg). The recommended maintenance dose is 20 mg once a day, which is reached at the beginning of the fourth week.
Posology for Patients with Renal Impairment
If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor should periodically monitor your kidney function.
Administration
Memantina TecniGen should be administered orally once a day. To get the most out of your medication, you should take it every day and at the same time. The tablets should be swallowed with a little water. The tablets can be taken with or without food.
Duration of Treatment
Continue taking Memantina TecniGen as long as it is beneficial for you. Your doctor should periodically evaluate the effects of your treatment.
If You Take More Memantina TecniGen Than You Should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service (telephone 91 562 04 20), indicating the medication and the amount taken.
Generally, taking an excessive amount of Memantina TecniGen should not cause you any harm. You may experience an increase in the symptoms described in section 4 "Possible Side Effects".
If you take an overdose of Memantina TecniGen, contact your doctor or seek medical advice, as you may need medical attention.
If You Forget to Take Memantina TecniGen
If you realize you have forgotten to take your dose of memantine, wait and take the next dose at the usual time.
Do not take a double dose to make up for the forgotten dose.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, Memantina TecniGen can cause side effects, although not everyone will experience them.
Generally, side effects are classified as mild to moderate.
Frequent (may affect 1 to 10 in 100 patients):
Uncommon (may affect 1 to 10 in 1,000 patients):
Rare (may affect less than 1 in 10,000 patients):
Frequency Not Known (frequency cannot be estimated from available data):
Alzheimer's disease has been associated with depression, suicidal ideation, and suicide. These events have been reported in patients treated with memantine.
If you consider any of the side effects you experience to be serious or if you notice any side effect not mentioned in this package leaflet, inform your doctor or pharmacist.
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the blister pack and carton after EXP. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and any unused medication in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Memantina TecniGen
The active ingredient is memantine hydrochloride. Each film-coated tablet contains 20 mg of memantine hydrochloride, equivalent to 16.62 mg of memantine.
The other components are microcrystalline cellulose, povidone K-25, sodium croscarmellose, and magnesium stearate in the tablet core; and hydroxypropylcellulose, hypromellose, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), and orange yellow S (E110) in the tablet coating.
Appearance of the Product and Package Contents
Memantina TecniGen is presented in the form of film-coated tablets of orange to pink color and elliptical biconvex shape.
Memantina TecniGen tablets are presented in packs of 28 and 56 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder
Tecnimede España Industria Farmacéutica, S.A.
Avda. de Bruselas, 13, 3º D.
28108 Alcobendas (Madrid) SPAIN
Manufacturer
Atlantic Pharma – Produções Farmacêuticas, S.A.
Rua da Tapada Grande, n.º 2; Abrunheira, 2710-089 Sintra, Portugal
This Medication is Authorized in the Member States of the European Economic Area with the Following Names:
Portugal: Memantina TecniGen
Italy: Memantina Tecnimede
Spain: Memantina TecniGen 20 mg film-coated tablets EFG
Date of the Last Revision of this Package Leaflet:July 2023
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/